|
| PFS | OS | |||||||
| Prognostic factors | Number of patients | PFS at 18 months | PFS at 36 months | Median PFS months | P-value | OS at 18 months | OS at 36 months | Median OS months | P-value |
| Whole group | 39 | 32.4% | 29.7% | 10.6 |
| 39.6% | 31.1% | 15.1 |
|
| Age |
|
|
|
|
|
|
|
|
|
| ≤47 | 20 | 25.0% | 25.0% | 8.6 | 0.45 | 33.0% | 27.5% | 14.0 | 0.604 |
| >47 | 19 | 35.3% | 35.3% | 12.5 |
| 47.1% | 35.3% | 16.3 |
|
| Sex |
|
|
|
|
|
|
|
|
|
| Male | 18 | 17.6% | 17.6% | 10.5 | 0.22 | 25.9% | 19.4% | 14.0 | 0.258 |
| Female | 21 | 40.0% | 40.0% | 12.3 |
| 50.0% | 40.0% | 15.0 |
|
| Smoking |
|
|
|
|
|
|
|
|
|
| Non-smoker | 27 | 34.6% | 34.6% | 9.1 | 0.65 | 45.3% | 37.1% | 15.0 | 0.486 |
| Smoker | 12 | 18.2% | 18.2% | 10.6 |
| 27.3% | 18.2% | 14.5 |
|
| Primary site |
|
|
|
|
|
|
|
|
|
| Nasopharynx | 11 | 63.6% | 63.6% | - | 0.01 | 71.6% | 71.7% | - | 0.006 |
| Other | 28 | 15.4% | 15.4% | 8.2 |
| 26.9% | 15.4% | 12.7 |
|
| Histology |
|
|
|
|
|
|
|
|
|
| SCC | 23 | 18.2% | 18.2% | 8.6 | 0.089 | 31.8% | 18.2% | 12.6 | 0.071 |
| Others | 16 | 46.7% | 46.7% | 16.0 |
| 51.9% | 51.9% | - |
|
| Grade |
|
|
|
|
|
|
|
|
|
| I and II | 22 | 21.1% | 21.1% | 5.4 | 0.061 | 31.6% | 21.1% | 8.3 | 0.072 |
| III and IV | 17 | 41.2% | 41.2% | 13.3 |
| 50.7% | 44.3% | 18.7 |
|
| T-stage |
|
|
|
|
|
|
|
|
|
| T1 and T2 | 12 | 50.0% | 50.0% | 19.5 | 0.05 | 62.5% | 50.0% | 28.5 | 0.082 |
| T3 and T4 | 27 | 19.2% | 19.2% | 5.4 |
| 25.0% | 20.8% | 8.3 |
|
| N-stage |
|
|
|
|
|
|
|
|
|
| N0 and N1 | 19 | 23.5% | 23.5% | 8.3 | 0.41 | 29.4% | 23.5% | 12.5 | 0.374 |
| N2 and N3 | 20 | 35.0% | 35.0% | 11.2 |
| 43.1% | 37.7% | 16.3 |
|
| Grade 3 - 4 |
|
|
|
|
|
|
|
|
|
| Toxicity* |
|
|
|
|
|
|
|
|
|
| No | 12 | 50.0% | 50.0% | 16.0 | 0.065 | 60.0% | 50.0% | 23.6 | 0.05 |
| Yes | 25 | 25.9% | 22.2% | 8.3 |
| 27.9% | 23.9% | 15.0 |
|